NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis

P Ruggeri1,2, L Cappabianca1,2, AR Farina1, L Gneo1 and AR Mackay1

We report a novel pro-apoptotic function for nerve growth factor (NGF) and its tropomyosin-related kinase A (TrkA) receptor in sensitizing TRAIL (TNF-related apoptosis-inducing ligand)-resistant SH-SYSY neuroblastoma (NB) cells to TRAIL-induced apoptosis, resulting in the abrogation of anchorage-independent tumourigenic growth in vitro. We show that the TRAIL-resistant SH-SYSY phenotype is cFLIP (cellular FLICE-like inhibitory protein) dependent and not due to low-level functional TRAIL receptor or caspase expression or an inhibitory equilibrium between functional and decoy TRAIL receptors or B-cell lymphoma 2 (Bcl-2) and BH3-only (Bcl-2 homology domain 3-only) family proteins. NGF sensitization of SH-SYSY cells to TRAIL-induced apoptosis was dependent upon TrkA expression, activation and subsequent sequestration of cFLIP. This reduces cFLIP recruitment to TRAIL-activated death receptors and increases the recruitment of caspase-8, leading to TRAIL-induced, caspase-dependent, type II apoptosis via the intrinsic mitochondrial pathway. This effect was temporary, inhibited within 6 h by nuclear factor-κ binding (NF-κB)-mediated increase in myeloid cell leukaemia-1 (Mcl-1) expression, abrogated by transient cFLIP or B-cell lymphoma-extra large (Bcl-xL) overexpression and optimized by NF-κB and Mcl-1 inhibitors. This novel mechanism adds an important pro-apoptotic immunological dimension to NGF/TrkA interaction that may not only help to explain the association between TrkA expression, better prognosis and spontaneous remission in NB, but also provides a novel potential pro-apoptotic therapeutic use for NGF, TRAIL and inhibitors of NF-κB and/or Mcl-1 in favourable and unfavourable NBs that express TrkA and exhibit cFLIP-mediated TRAIL resistance.

Cell Death Discovery (2016) 2, 16004; doi:10.1038/cddiscovery.2016.4; published online 1 February 2016

INTRODUCTION

During sympathetic nervous system (SNS) development, neuroblasts delaminate from the neural crest and migrate to form parasympathetic sympathetic ganglia before differentiating into the various cellular components of the SNS. This finely tuned process is associated with both resistance and sensitivity to apoptosis, ensuring sufficient cell numbers to form the fully functional SNS, while eliminating cellular excess. Within this context, neuroblast resistance and sensitivity to apoptosis is regulated by neurotrophins (nerve growth factor (NGF), BDNF, NT3 and NT4/5) and their corresponding receptors (tropomyosin-related kinase (Trk)-A, TrkB, TrkC, p75NTR and Sortilin). Active neurotrophins ligate TrkA, TrkB and TrkC to protect neuroblasts from apoptosis; TrkC in the absence of p75NTR and TrkA in the presence of p75NTR are pro-apoptotic in the absence of active neurotrophins, whereas p75NTR and Sortilin are pro-apoptotic upon pro-neurotrophin ligation in the absence of Trk receptor expression. This variety of potential pro- and anti-apoptotic outcomes is regulated by spatial and temporal changes in neurotrophin and neurotrophin receptor expression.1

Apoptosis is activated via the extrinsic and/or intrinsic pathways.1,2,3 The identification of tumour necrosis factor-α (TNFα) as the pro-apoptotic cytokine responsible for endotoxin-induced tumour necrosis4 paved the way for characterization of the extrinsic pathway and the subsequent identification of the TNFα pro-apoptotic cytokine family comprising TNFα, Apo1/Fas, Apo2L/TRAIL (TNF-related apoptosis-inducing ligand) and Apo3L that induce two types of apoptotic response through their cognate TNFR1, Apo1/Fasl, FasR, Apo3L/DR3, Apo2L/DR4 and DR5 death receptors.5,6 In type I cells, activated death receptors recruit FADD (Fas-associated protein with death domain) and caspase-8 (or caspase-10) to induce apoptosis via the activation of caspase-7 and caspase-3. In type II cells, low-level caspase-8 activation does not result in the direct activation of caspase-3 but cleaves the pro-apoptotic BH3-only (Bcl-2 homology domain 3-only) protein BID (BH3 interacting domain death agonist). Cleaved tBID translocates to the mitochondria and induces permeabilization of the outer mitochondrial membrane (OMM). This results in the release of the pro-apoptotic mitochondrial proteins cytochrome C, Omi/Htr2a and SMAC/DIABLO (second mitochondria-derived activator of caspases) into the cytosol that results in caspase-3-dependent apoptosis5,7 and/or caspase-independent death through the release of mitochondrial apoptosis-inducing factors (AIFs) and endonuclease G.8

Apo2L/TRAIL is a promising chemotherapeutic agent because of its selective pro-apoptotic action on tumour but not nontransformed cells5,8,9,10 that exhibit a multiplicity of redundant TRAIL resistance pathways.3,11 In tumour cells, TRAIL induces apoptosis by ligating functional DR4 and/or DR5 TRAIL receptors that recruit FADD and initiator caspase-8 (or -10) to the death-inducing complex DISC.5,6,14 In both type I and type 2 tumour cells, TRAIL-induced apoptosis is regulated by the equilibrium between functional (DR4 and DR5) and decoy (DcR1, DcR2 and OPG) TRAIL receptors, the level of caspase-3, caspase-8, caspase-9 and

1Department of Applied Clinical and Biotechnological Sciences, University of L’Aquila, Via Vetoio, Coppito 2, L’Aquila 67100, Italy.
2Correspondence: AR Mackay (andrewreay.mackay@univaq.it)
3These authors contributed equally to this work.
4Received 4 December 2015; accepted 4 December 2015; Edited by G Melino

© 2016 Cell Death Differentiation Association All rights reserved 2058-7716/16
www.nature.com/cddiscovery
NGF sensitizes TrkA SH-SYSY neuroblastoma cells to TRAIL

P Ruggeri et al

NGF sensitizes TRAIL-resistant TrkA SH-SYSY cells to TRAIL-induced apoptosis

In two-dimensional culture, TRAIL at concentrations from 10 ng to 1 μg/ml did not induce significant death of either nontransfected (NT), duplicate empty pcDNA3.1 vector (pcDNA)-transfected or duplicate TrkA-transfected SH-SYSY cell lines, confirming their TRAIL-resistant phenotypes (Figures 1a and b). NGF (100 ng/ml) also failed to induce significant death of NT SH-SYSY, pcDNA SH-SYSY or TrkA SH-SYSY cells (Figures 1a and b). In contrast, the combination of NGF (100 ng/ml) and TRAIL (200 ng/ml) induced a mean (± S.D.) of 68.7 ±13.8 and 66 ± 14.3% death in the two TrkA SH-SYSY cell lines but did not induce the death of either NT SH-SYSY or pcDNA SH-SYSY cells (Figures 1a and b). TrkA SH-SYSY cells that survived the effects of NGF plus TRAIL exhibited neurite-like projections, suggesting the initiation of neural differentiation (Figure 1c). In concentration studies, the death of TrkA SH-SYSY cells in the presence of NGF (100 ng/ml) was detected at TRAIL concentrations ≥ 50 ng/ml and plateaued with a mean (± S.D.) of 68.3 ±15.3% death at a concentration of 200 ng/ml (Figures 1a and d). The TRAIL-induced death of TrkA SH-SYSY cells was confirmed to be apoptotic by Tunel assay (Figure 1a), detection of DNA laddering (Figure 1e) and was abrogated by the caspase inhibitors z-DEVD-fmk (caspase-3), z-IETD-fmk (caspase-8) and z-LEHD-fmk (caspase-9) (see Figures 4d and e).

NGF/TRAIL inhibits TrkA SH-SYSY tumourigenic growth in vitro

The effect of TRAIL and NGF upon the tumourigenic activity of NT, pcDNA and TrkA SH-SYSY cell lines was assessed in substrate-independent tumourigenesis assays in vitro.

NT, pcDNA and TrkA SH-SYSY cells formed similar numbers of similar-sized tumour spheroids over 14 days in soft agar tumourigenesis assays, under basal conditions (Figures 2a and b, identical results were obtained for duplicate cell lines and results are displayed for single NT, pcDNA and TrkA SH-SYSY cell lines). The addition of TRAIL (200 ng/ml) to soft agar did not significantly reduce the tumourigenic activity of NT SH-SYSY, pcDNA SH-SYSY or TrkA SH-SYSY cells (Figures 2a and b). NGF (100 ng/ml) added to soft agar significantly reduced the number of tumour spheroids formed by TrkA SH-SYSY cells by a mean (± S.D.) of 58.5 ±9.1% (P < 0.0001, d.f. = 10) but did not inhibit the number of tumour spheroids formed by either NT SH-SYSY or pcDNA SH-SYSY cells over 14 days (Figures 2a and b). Furthermore, tumour spheroids formed by TrkA SH-SYSY cells in the presence of NGF (100 ng/ml) appeared to be less well formed (Figure 2c). The addition of NGF (100 ng/ml) plus TRAIL (200 ng/ml) to soft agar abrogated tumour spheroid growth by TrkA SH-SYSY cells, resulting in a mean (± S.D.) of 96.8% (P < 0.0001, d.f. = 10) inhibition when compared with untreated TrkA SH-SYSY cells and 92.5% (P < 0.0001, d.f. = 10) inhibition when compared with NGF-treated TrkA SH-SYSY cells (Figures 2a and b). In contrast, the combination of NGF plus TRAIL did not reduce the number of tumour spheroids formed by NT SH-SYSY or pcDNA SH-SYSY cells (Figures 2a and b).

SH-SYSY cells express all components required for TRAIL-induced apoptosis

Molecular characterization of the TRAIL-resistant SH-SYSY phenotype revealed similar levels of constitutive mRNA and protein expression for functional (DR4 and DR5) and decoy (DcR1 and DcR2) TRAIL receptors; caspase-3, caspase-8 and caspase-9; cFLIP-S and cFLIP-L; Bcl-2, B-cell lymphoma-extra large (Bcl-xL), myeloid cell leukaemia-1 (Mcl-1) and BID in NT SH-SYSY, pcDNA SH-SYSY and TrkA SH-SYSY cell lines (Figures 3a and b, identical results were obtained for duplicate cell lines and results are displayed for single NT, pcDNA and TrkA SH-SYSY cell lines). Indirect IF confirmed similar levels of DR4, DR5, DcR1 and DcR2 TRAIL receptors in NT SH-SYSY, pcDNA SH-SYSY and TrkA SH-SYSY cells, with an equilibrium in favour of functional rather than decoy receptors. Indirect IF confirmed cell surface DR4 and DR5 receptor expression in nonpermeabilized cells (Figure 3c). In TrkA SH-SYSY cells, NGF (100 ng/ml for 3 and 6 h) alone increased the expression of Mcl-1, Bcl-xL and DR5, decreased DcR2 expression, did not alter the expression of DR4, DcR1, caspase-3, caspase-8, caspase-9, cFLIP-S, cFLIP-L, Bcl-2 or BID and did not regulate the expression of any of these genes in either NT SH-SYSY or pcDNA SH-SYSY cells (Figures 4a and b, data displayed for TrkA SH-SYSY cells only). TRAIL (200 ng/ml for 3 and 6 h) alone did not alter the expression of these genes in NT SH-SYSY, pcDNA SH-SYSY or TrkA SH-SYSY cells (data not displayed). These data indicate that the TRAIL-resistant SH-SYSY phenotype does not result from a lack of expression of any single component of TRAIL-induced apoptosis; TrkA per se does not alter the expression of components of TRAIL-induced apoptosis in SH-SYSY cells and NGF stimulates Mcl-1 and to a lesser extent Bcl-xL, DR4 and DR5 expression in TrkA SH-SYSY cells.

NGF plus TRAIL induce type II apoptosis in TrkA SH-SYSY cells

TRAIL-induced apoptosis of NGF-sensitized TrkA SH-SYSY cells was associated with the cleavage of BID, caspase-3, caspase-8 and caspase-9, increased cytosolic levels of the mitochondrial proteins cytochrome C and Htr2a/OMI and reduced cytosolic levels of the caspase inhibitor XIAP (X-linked inhibitor of apoptosis) (Figure 4c, results displayed for a single TrkA SH-SYSY cell line only). The caspase-3 inhibitor z-DEVD-fmk (100 μM), caspase-8 inhibitor z-IETD-fmk (20 μM) and the caspase-9 inhibitor z-LEHD-fmk (50 μM) all significantly inhibited TRAIL-induced apoptosis of NGF-sensitized TrkA SH-SYSY cells (Figure 4d) from a mean (± S.D.) of 73.2 ±17% in untreated controls to 10 ± 18% (P < 0.0001, d.f. = 10), 12 ± 16.3%
Figure 1. NGF sensitizes TrkA SH-SYSY cells to TRAIL-induced apoptosis. (a) Representative phase contrast and fluorescent micrographs (bar = 100 μM) and (b) histograms demonstrating the marked induction of TrkA SH-SYSY but not NT or pcDNA SH-SYSY cell death following 16 h of incubation with NGF (100 ng/ml) plus TRAIL (200 ng/ml), compared with the lack of cell death in all three cell lines following overnight (16 h) incubation with either NGF (100 ng/ml) or TRAIL (200 ng/ml) alone. Results are displayed as the mean percentage (%) of alive (white) and dead (black) cells (± S.D.) in three independent experiments each performed in duplicate (*statistical significance). (c) Representative phase contrast micrographs demonstrating the effect of NGF plus TRAIL on the morphology of surviving TrkA SH-SYSY cells. (d) Histogram demonstrating dose-dependent induction of TrkA SH-SYSY cell death by TRAIL (10–500 ng/ml) in the presence but not absence of NGF (100 ng/ml). Results are displayed as the mean percentage (%) (± S.D.) of alive (white) and dead (black) cells in three independent experiments each performed in duplicate. (e) Representative ethidium bromide stained agarose gel demonstrating laddering of DNA purified from TrkA SH-SYSY cells treated for 16 h with NGF (100 ng/ml) plus TRAIL (200 ng/ml) but not from TrkA SH-SYSY cells treated with either NGF (100 ng/ml) or TRAIL (200 ng/ml) alone.
NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL (P Ruggeri et al) | Cell Death Discovery (2016) 16004 © 2016 Cell Death Differentiation Association

Figure 2. NGF plus TRAIL abrogates the tumourigenic activity of TrkA SH-SY5Y cells in vitro. (a) Representative photograph and (b) histogram demonstrating significant inhibition of TrkA SH-SY5Y but not NT SH-SY5Y or pcDNA SH-SY5Y tumourigenic activity in vitro by NGF (100 ng) alone or in combination with TRAIL (200 ng). Results are displayed as the mean (± S.D.) number of tumours in 10×10 magnification fields in triplicate experiments each performed in duplicate (statistical significance). (c) Representative phase contrast micrographs demonstrating tumour spheroid appearance of TrkA SH-SY5Y cells in vitro in the absence (control) or presence of NGF (100 ng/ml) plus NGF (100 ng/ml) or TRAIL (200 ng/ml) alone.

(P < 0.0001, d.f. = 10) and 15 ± 23% (P = 0.0005, d.f. = 10), respectively (Figure 4e). The TrkA tyrosine kinase inhibitors CEP-701, Gö697642 and GW441756 also significantly inhibited TRAIL-induced apoptosis of NGF-sensitized TrkA SH-SY5Y cells from a mean (± S.D.) of 73.2 ± 17% in controls to 17 ± 14.5% (P < 0.0001, d.f. = 10), 8 ± 13.3% (P < 0.0001, d.f. = 10) and 9.8 ± 10% (P < 0.0001, d.f. = 10), respectively (Figure 4d, phase contrast GW441756 only; and Figure 4e).

Transient Bcl-xL overexpression (Figure 5a) significantly reduced TRAIL-induced apoptosis in NGF-sensitized TrkA SH-SY5Y cells from a mean (± S.D.) of 68.5 ± 13 to 25.1 ± 15% (P < 0.0003, d.f. = 10; Figure 5b). These data confirm that TRAIL-induced apoptosis of NGF-sensitized TrkA SH-SY5Y cells is dependent upon TrkA activity, is caspase dependent and is mediated through the intrinsic mitochondrial pathway.

The TRAIL-resistant SH-SY5Y phenotype is cFLIP dependent NT SH-SY5Y, pcDNA SH-SY5Y and TrkA SH-SY5Y cells all exhibited similar constitutive high-level cFLIP mRNA and protein expression (Figures 3a and b). The small interfering RNA (siRNA) cFLIP knockdown (Figure 5c) sensitized TrkA SH-SY5Y cells to TRAIL-induced apoptosis in the absence of NGF, resulting in a mean (± S.D.) of 46 ± 16.2% death (P < 0.0001, d.f. = 10, compared with siRNA-transfected controls; Figure 5d). Transient cFLIP overexpression (Figure 5e) significantly reduced TRAIL-induced apoptosis in NGF-sensitized TrkA SH-SY5Y cells from a mean (± S.D.) of 69 ± 11.6% to 36.4 ± 12.6% (P = 0.0009, d.f. = 10; Figure 5f). These data identify cFLIP as a major mediator of the TRAIL-resistant SH-SY5Y phenotype and regulator of TRAIL-induced apoptosis in NGF-sensitized TrkA SH-SY5Y cells.

NGF induces TrkA–cFLIP binding NGF (100 ng/ml for 1–6 h) did not reduce cFLIP mRNA or protein expression in TrkA SH-SY5Y cells nor induce cFLIP degradation (Figure 4a), suggesting an alternative mechanism for sensitization to TRAIL-induced apoptosis. NGF (100 ng for 1 and 6 h), however, induced a binding interaction between TrkA and endogenous cFLIP (Figure 6a) and also between TrkA and...
exogenous FLAG-tagged cFLIP transiently overexpressed in TrkA SH-SY5Y cells (Figure 6b). The TrkA tyrosine kinase inhibitor CEP-701 (100 nM) reduced the binding interaction between TrkA and FLAG-tagged cFLIP detected following 6 h of incubation with NGF, consistent with a requirement for TrkA tyrosine kinase activity (Figure 6b).

NGF reduces cFLIP recruitment to activated TRAIL death receptors in TrkA SH-SY5Y cells

The possibility that NGF sensitization of TrkA SH-SY5Y cells to TRAIL-induced death results from cFLIP sequestration was confirmed by comparing cFLIP and caspase-8 levels associated with TRAIL-ligated DR4 death receptor complexes purified from TrkA SH-SY5Y cells preincubated for 6 h in the presence or absence of NGF (100 ng/ml) before 1 h of treatment with biotinylated-TRAIL (500 ng/ml). Ligand-affinity purified, TRAIL-ligated, DR4-positive death receptor complexes from TrkA SH-SY5Y cells that had been pretreated for 6 h with NGF (100 ng/ml) before being treated for 1 h with biotinylated-TRAIL (500 ng/ml) contained lower levels of cFLIP, higher levels of caspase-8 and similar levels of DR4 when compared with complexes purified from TrkA SH-SY5Y cells treated with biotinylated-TRAIL (500 ng/ml), confirming that NGF reduces cFLIP recruitment and increases caspase-8 recruitment to TRAIL-activated death receptors in TrkA SH-SY5Y cells. Similar complexes...
NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced caspase-dependent type II apoptosis and regulates Mcl-1 but not FLIP expression. (a) Western blots demonstrating NGF stimulation of Mcl-1, Bcl-xL and DR5 protein expression, and the maintenance of TrkA tyrosine phosphorylation in TrkA SH-SY5Y cells over a 1 to 6 h time course. (b) Agarose gels demonstrating NGF stimulation of Mcl1 and Bcl-xL but not Bcl-2 mRNA expression in TrkA SH-SY5Y cells over a 1–6 h time course. (c) Representative western blots demonstrating changes in cytoplasmic caspase-8, caspase-9, caspase-3, BID, cytochrome C, OMI/Htr2a and XIAP but not in cFLIP or α-tubulin in TrkA SH-SY5Y cells treated with a combination of NGF (100 ng/ml) plus TRAIL (200 ng/ml) but not with NGF (100 ng/ml) or TRAIL (200 ng/ml) alone. (d) Representative phase contrast micrographs (bar = 100 μM) and (e) histogram demonstrating the inhibition of TRAIL-induced apoptosis by z-VAD-fmk, z-IETD-fmk, z-LEHD-fmk caspase inhibitors and the TrkA kinase inhibitors CEP-701 (CEP), Gö6976 (Go) and GW441756 (GW) (histogram only). Results are displayed as the mean percentage (%) (± S.D.) alive (white) or dead (black) cells in three experiments, each performed in duplicate (*statistical significance).
The siRNA Mcl-1 knockdown in TrkA SH-SY5Y cells reduced constitutive Mcl-1 expression and inhibited NGF stimulation of Mcl-1 expression (Figure 7a). Mcl-1 knockdown also prevented loss of sensitivity to TRAIL-induced apoptosis, following 6 h of preincubation with NGF (Figures 7b and c). Mcl-1 knockdown, however, did not sensitize NT SH-SY5Y, pcDNA SH-SY5Y or TrkA SH-SY5Y cells to TRAIL-induced apoptosis in the absence of NGF (data not displayed), confirming that Mcl-1 was not directly responsible for the TRAIL-resistant SH-SY5Y phenotype despite being largely responsible for the loss of sensitivity to TRAIL, observed following 6 h of preincubation with NGF.

The transcription factor NF-κB regulates Mcl-1 expression and is activated by NGF in TrkA SH-SY5Y cells. NF-κB involvement in NGF-stimulated Mcl-1 expression and loss of sensitivity to TRAIL following 6 h of NGF preincubation was confirmed by transient expression of dominant-negative NF-κB (dn-NF-κB) and also by incubation with the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC). Both dn-NF-κB and PDTC reduced NGF stimulation of Mcl-1 expression in TrkA SH-SY5Y cells (Figure 7a) and prevented loss of sensitivity to TRAIL-induced apoptosis in TrkA SH-SY5Y cells, following 6 h of NGF preincubation (Figures 7b and c).

**DISCUSSION**

In the present study, we show that NGF sensitizes TrkA-expressing SH-SY5Y cells to TRAIL-induced apoptosis, unveiling a novel pro-apoptotic immunological dimension to NGF interaction with the TrkA receptor in transformed human neuroblasts. This mechanism
depends upon TrkA expression, TrkA activation, caspase and BID cleavage and results in type II apoptosis through the intrinsic mitochondrial pathway. We identify cFLIP as the major mediator of the TRAIL-resistant SH-SY5Y phenotype and provide evidence that NGF sensitization to TRAIL-induced apoptosis results from cFLIP sequestration by NGF-activated TrkA. This reduces cFLIP and increases caspase-8 recruitment to TRAIL-activated death receptors, resulting in the cleavage of caspase-8 and BID, in turn leading to OMM permeabilization and type II cell apoptosis through the intrinsic mitochondrial pathway. We identify NF-κB and Mcl-1 as endogenous inhibitors and NF-κB and Mcl-1 inhibitors as exogenous optimizers of this novel NGF/TrkA-mediated TRAIL sensitization response.

The TRAIL-resistant SH-SY5Y phenotype could not be explained by the absence of any single component of the TRAIL-induced apoptotic pathway and, in contrast to some reports, our SH-SY5Y cell lines exhibited constitutive functional TRAIL receptors and caspase-8 expression. Furthermore, the relatively low level of decoy (DcR1 and DcR2) relative to functional (DR4 and DR5) TRAIL receptors expression observed suggests that the TRAIL-resistant SH-SY5Y phenotype was not the result of an anti-apoptotic equilibrium between functional and decoy TRAIL receptors. Indirect IF and ligand affinity TRAIL receptor purification confirmed that functional TRAIL receptors were expressed at the cell surface, indicating that differential localization of functional and decoy TRAIL receptors was unlikely to be responsible for the TRAIL-resistant phenotype, as reported previously.

SH-SY5Y cell lines also exhibited low-level expression of the Bcl-2 family proteins, Bcl-2, Bcl-xL and Mcl-1, suggesting that TRAIL resistance was unlikely to depend upon an anti-apoptotic equilibrium between Bcl-2 and BH3-only family proteins.

We identify cFLIP as the major mediator of the TRAIL-resistant SH-SY5Y phenotype, based upon the observations that: TRAIL-resistant cell lines exhibited high-level expression of cFLIP-IgG, IgG and cFLIP Con NGF, TrkA- Con No NGF, 1hr NGF, 6hr NGF, 6hr NGF + CEP-701. We co-immunoprecipitation western blots demonstrating endogenous cFLIP pull-down of TrkA in immunoprecipitates from total cell extracts (1 mg) of NGF-treated (100 ng/ml for 6 h) but not untreated TrkA SH-SY5Y cells. Representative western blots demonstrating exogenous FLAG-tagged cFLIP pull-down of TrkA by immunoprecipitates in whole cell extracts (300 μg) of NGF-treated (100 ng/ml for 1 and 6 h) but not untreated TrkA SH-SY5Y cells transiently transfected with a FLAG-tagged cFLIP expression vector. Note the reduced levels of TrkA pulled down by exogenous FLAG-tagged cFLIP in TrkA SH-SY5Y cells co-treated with CEP-701 (100 nM) and NGF for 6 h. Input levels of TrkA and cFLIP are also provided (Input). Representative western blots demonstrating reduced levels of cFLIP and increased levels of caspase-8 in TRAIL-activated DR4-positive death receptor complexes purified from TrkA SH-SY5Y cells preincubated for 6 h with NGF (100 ng/ml) and then treated for 1 h with biotinylated-TRAIL (500 ng/ml) (NGF TRAIL) as compared with TrkA SH-SY5Y cells preincubated for 6 h in the absence of NGF then treated for 1 h with biotinylated-TRAIL (500 ng/ml) (TRAIL) and TrkA-SH-SY5Y cells treated for 6 h with NGF (100 ng/ml) alone (NGF), and untreated TrkA SH-SY5Y cells (Con). Input levels of caspase-8, cFLIP and α-tubulin are provided (Input).
cFLIP (S and L); TRAIL alone did not induce the cleavage of either caspase-8 or BID consistent with a block at the death receptor level; siRNA cFLIP knockdown sensitized TrkA SH-SY5Y cells to TRAIL-induced apoptosis in the absence of NGF; and transient cFLIP overexpression inhibited TRAIL-induced apoptosis in NGF-sensitized TrkA SH-SY5Y cells. However, NGF did not reduce cFLIP expression or induce cFLIP degradation in TrkA SH-SY5Y cells, implicating an alternative sensitization mechanism. A sensitization mechanism based upon cFLIP sequestration was suggested by NGF stimulation of a CEP-701-sensitive binding interaction between NGF-activated TrkA and cFLIP and was confirmed by a reduction in cFLIP and increase in caspase-8 recruitment to TRAIL-activated death receptor complexes. This adds to a recent report that TrkA binds cFLIP during NGF-induced neuritogenesis, characterizes TrkA as a TRAIL-activated TRAIL receptor competitor and supports reports that cFLIP competes with caspase-8 to bind TRAIL-activated TRAIL receptors. This adds a novel dimension to TrkA function as a regulator of cFLIP involvement in death receptor-mediated apoptosis. The sequestration of cFLIP may also extend to MAPKs.

Figure 7. NGF sensitization of TrkA SH-SY5Y cells to TRAIL-induced apoptosis is temporary and regulated by NF-κB and Mcl-1. (a) Representative western blots demonstrating NGF (100 ng/ml for 6 h) stimulation of constitutive Mcl-1 expression in whole cell extracts (30 μg) from untreated, control siRNA-treated and transient empty pcDNA-transfected TrkA SH-SY5Y cells, reduced constitutive Mcl-1 expression and loss of NGF-stimulated Mcl-1 expression in total extracts (30 μg) from TrkA SH-SY5Y cells transiently transfected with Mcl-1-specific siRNA duplexes and the loss of NGF-stimulated Mcl-1 expression in cells transiently transfected with dn-NF-κB. (b) Representative phase contrast micrographs demonstrating TRAIL-induced apoptosis of TrkA SH-SY5Y cells following 1 h (NGF 1 h pre-inc TRAIL) but not 6 h of NGF preincubation (NGF 6 h pre-inc TRAIL) (bar = 100 μM), and (c) histogram demonstrating TRAIL-induced apoptosis following 6 h of preincubation with NGF in TrkA SH-SY5Y cells transiently transfected with Mcl-1-specific siRNA duplexes, dn-NF-κB expression vector or treated with the NF-κB inhibitor PDTC but not in cells transiently transfected with the empty pcDNA expression vector or nontransiently transfected 6 h NGF pretreated TrkA SH-SY5Y cells (Con). Results are displayed as the mean percentage (%) (± S.D.) alive (white) or dead (black) of total cells in three independent experiments, each performed in duplicate (*significant difference).
that also bind cFLIP, but it remains to be determined whether this may extend to other NT receptors.

NGF sensitization of TrkA SH-SYSY cells to TRAIL-induced apoptosis was dependent upon TrkA tyrosine kinase activity and was prevented by the TrkA inhibitors CEP-701, G6976, and GW441756. Apoptosis was also caspase dependent and prevented by the caspase-3 inhibitor z-VAD-fmk, the caspase-8 inhibitor z-IETD-fmk, and the caspase-9 inhibitor z-LEHD-fmk. Bcl-xL overexpression inhibited apoptosis, confirming intrinsic mitochondrial apoptosis pathway involvement that was also supported by the induction of Bid cleavage, increased cytosolic levels of the pro-apoptotic mitochondrial proteins cytochrome C and OMI/Htr2a and reduced cytosolic levels of the anti-apoptotic protein XIAP, consistent with OMM permeabilization and type II cell apoptotic behaviour.

NGF sensitization of TrkA SH-SYSY cells to TRAIL-induced apoptosis was temporary and in preincubation studies was detected following preincubation with NGF for 1 h but not 6 h. This time-dependent loss of sensitivity to TRAIL did not associate with the loss of TrkA tyrosine phosphorylation or a reduction in the binding interaction between TrkA and cFLIP. Furthermore, it was also associated with an increase in the expression of functional (DR4 and DR5) over decoy (DcR1 and DcR2) TRAIL receptors, excluding a potential role for an inhibitory equilibrium between functional and decoy TRAIL receptors. Loss of sensitivity did, however, associate with a marked increase in the expression of the mitochondrial apoptosis inhibitors Mcl-1 and to a lesser extent Bcl-xL. Mcl-1 involvement was confirmed by siRNA knockdown that not only prevented NGF stimulation of Mcl-1 expression but also prevented the loss of TrkA SH-SYSY cell sensitivity to TRAIL-induced apoptosis following 6 h of preincubation with NGF. In contrast to its effects upon TRAIL receptor, Mcl-1 and Bcl-xL expression, NGF did not alter the expression of caspases, Bcl-2, BID or BAX.

The transcription factor NF-κB regulates Mcl-1 expression and is activated by NGF in TrkA SH-SYSY cells. As a role for NF-κB in the regulation of sensitivity to TRAIL was also confirmed using the NF-κB inhibitors dn-NF-κB and PDTC, both of which reduced NGF stimulation of Mcl-1 expression and prevented the loss of TrkA SH-SYSY cell sensitivity to TRAIL-induced apoptosis following 6 h of preincubation with NGF. Interestingly, NGF stimulated Mcl-1 and Bcl-xL, but not Bcl-2 expression in TrkA SH-SYSY cells. Although all three genes have been reported to be NF-κB-regulated, Bcl-1 is differentially regulated by Bcl-2 transcription factor CREB (cAMP response element-binding protein) that is inhibited in SH-SYSY cells. We are further investigating this differential regulation of Mcl-1, Bcl-xL and Bcl-2.

The combination of NGF plus TRAIL inhibited TrkA SH-SYSY tumourigenicity by >95%, more than expected, considering that NGF plus TRAIL induced no more than 70% cell death in a temporary sensitization effect. This can be explained by the differentiation promoting effects of NGF (see this study, and Poluha et al. and Taconelli et al.) that, despite not inducing apoptosis, caused 50% inhibition of TrkA SH-SYSY tumourigenicity in the absence of TRAIL.

In conclusion, we report a novel important pro-apoptotic immunological dimension to the interaction between NGF and the TrkA receptor in sensitizing neuroblastoma cells to TRAIL-induced apoptosis. We propose that this mechanism depends upon cFLIP sequestration by activated TrkA receptors and characterizes TrkA as a novel competitive regulator of TRAIL-induced apoptosis that competes with death receptor complexes for cFLIP. Our observations may help to explain the association between TrkA expression, better prognosis and spontaneous remission in NB and provide a novel potential pro-apoptotic therapeutic strategy, to be developed in the future, for the use of ‘painless’ forms of NGF or alternative TrkA agonists, together with TRAIL and inhibitors of NF-κB and/or Mcl-1 in favourable and unfavourable NBs that express TrkA and exhibit cFLIP-mediated TRAIL resistance. This novel approach may work best as a first-line therapy, as TRAIL receptor activation has recently been reported to promote mutated ki-Ras-driven metastatic progression and ki-Ras mutations are detected in relapsed but not primary NBs.

MATERIALS AND METHODS

NT, pcDNA control-transfected and TrkA-transfected SH-SYSY NB cell lines have been described previously. Cells were grown in RPMI, supplemented with appropriate antibiotics (Zeocin for stable transfectants, penicillin and streptomycin) and 10% fetal calf serum. TrkA inhibitors G6976 and GW441756, the NF-κB inhibitor PDTC, the cell-permeable caspase-3 inhibitor z-VAD-fmk, caspase-8 inhibitor z-IETD-fmk and caspase-9 inhibitor z-LEHD-fmk. NGF and human recombinant TRAIL were purchased from Sigma-Aldrich (St. Louis, MO, USA). The pan Trk inhibitor, CEP-701, was kindly supplied by Cephalon Inc. (West Chester, PA, USA). Antibodies against TrkA, α-tubulin, cFLIP, caspase-8, caspase-9, Bcl-I and Mcl-I were purchased from Santa Cruz (CA, USA). Antibodies against phosphorylated Y674/675 TrkA and Caspase-3 were from Cell Signalling (Danvers, MA, USA). Antibodies against DR4, DR5, DcR1 and DcR2 were from Abcam (Cambridge, UK). Hybrid C-extra nitrocellulose membranes and ECL solutions were purchased from Amersham (Bedford, UK). RNA easy RNA purification kits were purchased from Qiagen (Hilden, Germany). Mammalian pcDNA expression vectors for Bcl-xL and Flag-tagged cFLIP were kindly provided by Dr. Francesca Zazzeroni (University of L’Aquila, L’Aquila, Italy) and have been described previously. The dn-NF-κB expression vector has been previously described.

Transient overexpression of Bcl-xL, cFLIP and dn-NF-κB Bcl-xL, flag-tagged cFLIP and dn-NF-κB were overexpressed in SH-SYSY cell lines by transient transfection of mammalian expression vectors bearing Bcl-xL, FLAG-tagged cFLIP or dn-NF-κB. Briefly, 0.6 μg/ml of each vector was transfected into subconfluent cell cultures using FUGENE transfection reagent as directed by the manufacturer (Promega, Madison, WI, USA). At 6 h of transfection, medium was replaced with fresh growth medium (RPMI/10% FCS/glutamine plus antibiotic) and the cells were left for 48 h, at which time they were utilized for experimentation. Overexpression of Bcl-xL and Flag-tagged cFLIP was verified by western blotting of total cell extracts (20 μg).

siRNA cFLIP and Mcl-1 knockdown

The cFLIP and Mcl-1 expression was knocked down in NB cells using a TriFECTa Dicer-Substrate RNAi kit, employing three cFLIP-specific or Mcl-1-specific Dicer-Substrate siRNA duplexes, as described by the manufacturer (Integrated DNA Technologies, Coralville, IA, USA). Briefly, cells were subjected to 48 h of transient transfection with either 25 nM cFLIP or Mcl-1 siRNA duplexes, using INTERFERin in vitro transfection reagent, as described by the manufacturer (Polyplus Transfection Inc., New York, NY, USA). Sham-transfected controls received transfection reagent alone. The siRNA knockdown of cFLIP and Mcl-1 expression was confirmed by western blot comparison with a tubulin-in whole cell extracts (20 μg).

Mcl-1 siRNA sets were as follows: 5′-AGCUCUUAGUUGAUCAGAAU-3′ and 5′-UUUGUUGGUAUUGAUGACUAUCAGCCGAUA-3′; 5′-GGAAAAACUUAGUAUUAACUCUUAGUGAUGUGACU-3′; 5′-CCUCUGAUAUUAACCCACCAAC-3′ and 5′-CAAGUGGCAUGUGAUGUGUGGT-3′ and 5′-AACCCUUUCAUUAUGUCUAUGUGUG-3′; cFLIP siRNA sets were as follows: 5′-UGAGUUGGAGCAUAAGUUGUGUGGT-3′ and 5′-AACCAGAUUGAAUGCUUCAACAC-3′; 5′-CGAGAACCCUUGUGAUGUUGUUGUGUAC-3′ and 5′-CUAGGAGAAGCUGGACAAGGCGUUGACG-3′; 5′-GCGACGAGCUGAUGAAUGUUGGUG-3′; and 5′-UGUAUUGCUUGUUAUGUUGUGUGGT-3′.

Transfection efficiency was confirmed using a HPRT-S1 DS positive control and validated using a negative control duplex (NC1) not present in the human genome, as described by the manufacturer (Integrated DNA Technologies; www.IDTDNA.com).
RNA purification and reverse transcription-PCR (RT-PCR)

RT reactions were performed on total RNAs (1 μg), purified using RNAEasy Plus, as described by the manufacturer (Qiagen) using the Moloney Murine Leukemia virus RT kit as detailed by the manufacturer (LifeTechnologies, Inc., Paisley, UK). RT reactions were subjected to PCR using the following primers: GAP: 5′-AGGTCCACCTGAGACTGT-3′ (forward) and 5′-CTGCA CCACAACTGCTTAG-3′ (reverse) (300 bp); TrkA: 5′-GAAGACTCAGTTGTCTT-3′ (forward) and 5′-ATTGACGAGAGCATGATTGA-3′ (reverse) (452 bp); Bcl-2: 5′-GAAGATTGCTGCAAATGCAAATGACTG-3′ (forward) and 5′-CTCTGAGCTTGTGGGATGTG-3′ (reverse) (612 bp); Dr2: 5′-CCCGGCAGGACGAAAGATT-3′ (forward) and 5′-CTCTGGACGTGGCTTTT-3′ (reverse) (418 bp); Dr5: 5′-ACCTTCTGTTCCGTCGTTG-3′ (forward) and 5′-GGCTCTCAGCTTTGCTGCA-3′ (reverse) (214 bp); Drs: 5′-CTGAAGAGCC ATCTGGCCTAG-3′ (forward) and 5′-CAGATGTCCATCACTCTTAG-3′ (reverse) (347 bp); cFLIPs: 5′-GGAGTCCTTGTGGATGTG-3′ (forward) and 5′-ATACGAGGACAATGGCGATAG-3′ (reverse) (241 bp); cFLIP: 5′-GGCTCCAGA GAGTTGTAAGGT-3′ (forward) and 5′-AGCTTCTTCAGCTGATGTCG-3′ (reverse) (249 bp); Bcl-2: 5′-GACCTCCGAGAATGCTGCGG-3′ (forward) and 5′-CAGACTTCCAAGGGCAAC-3′ (reverse) (356 bp); Bcl-xL: 5′-GTGATTTTGGCAAGGGAC-3′ (forward) and 5′-GGACGGCCGGTCTGGGATT CTTG-3′ (reverse) (373 bp); caspase-8: 5′-TCTGGAGCTATCCTGCTGCTG-3′ (forward) and 5′-CTGGCTTGTGCTGTTAG-3′ (reverse) (427 bp); caspase-10: 5′-GGAGCTCTTGGCCCTGCGTACTG-3′ (forward) and 5′-CTGACGCT CCTGGTGG-3′ (reverse) (293 bp); caspase-3: 5′-TTAATAAAGCTATCCTGAAAGACT-3′ (forward) and 5′-TTATGATTAATAGTAGCTTTTTGG-3′ (reverse) (849 bp); BAX: 5′-AAGGAAGCTGGACCACGTTT-3′ (forward) and 5′-GGAGGAAAGTCCAGTAC-3′ (reverse) (256 bp); Mcl-1: 5′-AGGCCAATGGGCGAGCTG-3′ (forward) and 5′-TGTCAGATTTCGCAAGCT-3′ (reverse) (121 bp).

For each primer set, PCRs were performed on reverse transcription reactions serially diluted from 1 to 1:1000. Reactions below saturation were compared by densitometric analysis of Jpeg images of ethidium bromide stained gels, using ImageJ64 software.22

Analysis of apoptosis and the cell death assay

TRAIL-induced apoptosis was confirmed by in situ Tunel assay as described by the manufacturer (R&D Systems, Minneapolis, MN, USA). For DNA ladder analysis, cells were collected by centrifugation at 5000 r.p.m. for 5 min, lysed, incubated at room temperature for 10 min and then incubated for 5 min at 65 °C. Samples, cooled to room temperature for 5 min, were mixed with 700 μl of chloroform–isoamyl alcohol and centrifuged for 5 min at 12 000 r.p.m. The aqueous (upper) phase was transferred, an equal volume of cold isopropanol was added, mixed gently by inversion and centrifuged for 5 min at 12 000 r.p.m. The supernatant was discarded and pellet air-dried for 30 min. Dried DNA was dissolved in 50 μl of distilled water, quantified in a spectrophotometer (NanoDrop 1000, Wilmington, DE, USA) and analysed by 1.5% agarose gel electrophoresis.

Cell death was routinely assayed using a modification of previously described methods.23,24 Briefly, cells were washed once in Ca2+-free PBS, detached with ice-cold PBS containing 1 mM EDTA, transferred to sterile 15 ml tubes, centrifuged for 5 min at 1000 × g at 4 °C, washed with ice-cold PBS and repelleted by centrifugation at 1000 × g for 5 min at 4 °C. Cell pellets were resuspended in 25 μl of PBS containing 2 μl of acidine orange/ethidium bromide solution (100 μg/ml acidine orange and 100 μg/ml ethidium bromide in PBS) plated onto glass slides and examined immediately under a Zeiss (Carl Zeiss, Oberkochen, Germany) Axiosplora fluorescence microscope. Representative fields were digitally photographed under identical exposure conditions and the number of dead cells (orange/red nuclei) and live cells (green nuclei) counted. In addition to this assay, phase contrast micrographs of parallel cultures were used to confirm changes in the relative percentage of adherent and suspension (predominantly apoptotic) cells following TRAIL treatment.

Tumour growth in soft agar

For substrate-independent tumour growth assays, 1 × 104 cells in single-cell suspension (passed through a gauge × 18 syringe needle) were mixed in a 0.3% solution of agar (BiTech Difico-BD, Milan, Italy) in RPMI containing 5% FCS at 37 °C, with or without NGF (100 ng/ml) and/or TRAIL (200 ng/ml) and layered onto a solid 0.6% agarose substrate also with and without NGF and/or TRAIL prepared in the same growth medium. Following top phase solidification, complete medium was added and replaced every 2 days. Tumour spheroid growth was monitored over a 14-day period by phase contrast microscopy. Tumour spheroids were counted in 10 random fields at × 10 magnification.

Isolation of TRAIL-activated TRAIL receptor complexes

TRAIL-ligated death receptor complexes were purified from TrkA SH-SY5Y cells by ligand affinity precipitation, as previously described.25 Briefly, biotinylated TRAIL was prepared by incubating TRAIL (1 mg/ml) with Sulfo-NHS-LC-Biotin (1mg/ml; Thermo Fisher Scientific, Waltham, MA, USA) for 1 h on ice. The reaction was stopped by adding 1 : 10 volume of 1 M Tris-HCl (pH 7.5) and unincorporated biotin removed by buffer exchange into 150 mM NaCl, 30 mM HEPES (pH 7.5) using PD-10 columns (Amersham Pharmacia Biotech, Piscataway, NJ, USA). For ligand affinity precipitation, cells (5 × 105 cells per sample) were washed twice in RPMI at 37 °C and incubated with 1 μg/ml biotinylated TRAIL for 1 h. Death receptor complex formation was stopped by the addition of 15 volumes of ice-cold PBS and cells were then lysed in 4.5 ml of lysis buffer (30 mM TRIS-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, supplemented with complete protease inhibitor cocktail; Roche Diagnostics, Mannheim, Germany). TRAIL receptor protein complexes were precipitated from lysates by co-incubation with 20 μl of Streptavidin beads (Pierce) for 3 h at 4 °C with rotation. Ligand affinity precipitates were washed twice in lysis buffer, eluted from beads in reducing SDS-PAGE sample buffer and subjected to SDS-PAGE western blotting.

Statistical analysis

Data were analysed statistically by Student’s t-test and statistical significance was associated with probabilities of <0.05.

ABBREVIATIONS

NB, neuroblastoma; TNF, tumour necrosis factor; TRAIL, TNF-related apoptotic-inducing ligand; cFLIP, cellular FLICE-like inhibitory protein; NF-κB, nuclear factor-κ binding; dn-NF-κB, dominant-negative NF-κB; NGF, nerve growth factor; Trk, tropomyosin-related kinase; Mcl-1, myeloid cell leukaemia-1; Bcl-2, B-cell lymphoma 2; Bcl-xl, B-cell lymphoma extra large; BH3-only, Bcl-2 homology domain 3-only; BID, BH3 interacting domain death agonist; FADD, Fas-associated protein with death domain; OMM, outer mitochondrial membrane; DR, decoy receptor; sRNA, small interfering RNA; XIAP, X-linked inhibitor of apoptosis; AIF, apoptosis-inducing factor; PDI, protein disulfide isomerase; NT, nontransfected; CREB, cAMP response element-binding protein; Bcl-2, Tris-buffered saline and Tween-20; SDSPAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; RT-PCR, reverse transcription-PCR; SMAC/DIABLO, second mitochondria-derived activator of caspases.

© 2016 Cell Death Differentiation Association Cell Death Discovery (2016) 16:004
ACKNOWLEDGEMENTS
This work was supported by the Maugeri Foundation.

COMPETING INTERESTS
The authors declare no conflict of interest.

REFERENCES
1 Rupprecht F, Farina AR, Cappabianca L, Di Ianni N, Ragone M, Merolle S et al. Neutrophin and neutrophin receptor involvement in human neuroblastoma. In: Shimada H (ed). Neuroblastoma. Intech: Rijeka, Croatia, 2013.
2 Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest 2015; 125: 487–489.
3 Xiong S, Mu T, Wang G, Jiang X. Mitochondria-mediated apoptosis in mammals. Protein Cell 2014; 5: 737–740.
4 Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–3670.
5 Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305–1308.
6 Russo M, Mupo A, Spagnuolo C, Russo GL. Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol 2010; 80: 674–682.
7 Tatt SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621–632.
8 Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004; 23: 2785–2796.
9 Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4796–4811.
10 Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2 tumor necrosis factor-related apoptosis-inducing ligand (rhApopto/TRA1). J Clin Oncol 2006; 26: 3621–3630.
11 Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001; 6: 191–197.
12 Hall MA, Cleveland JL. Clearing the TRAIL for cancer therapy. Cancer Cell 2007; 12: 4–6.
13 Van Dijk M, Halpin-McCormick A, Sessler T, Samali A, Szegezdi E. Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis 2013; 4: e702.
14 Martinez-Lostao L, Marzo I, Anel A, Naval J. Targeting the Apo2L/TRA1 system for the therapy of autoimmune diseases and cancer. Biochem Pharmacol 2012; 83: 1475–1483.
15 Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cell Death Discovery (2016) 16004 © 2016 Cell Death Differentiation Association
16 Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2004; 23: 2785–2796.
17 Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2 tumor necrosis factor-related apoptosis-inducing ligand (rhApopto/TRA1). J Clin Oncol 2006; 26: 3621–3630.
18 Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001; 6: 191–197.
19 Hall MA, Cleveland JL. Clearing the TRAIL for cancer therapy. Cancer Cell 2007; 12: 4–6.
20 Van Dijk M, Halpin-McCormick A, Sessler T, Samali A, Szegezdi E. Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis 2013; 4: e702.
21 Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol 2015; 5: 1–20.
22 Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21: 2283–2294.
23 Yang X, Thiele CJ. Targeting the tumour necrosis factor-related apoptosis-inducing ligand pathway in neuroblastoma. Cancer Lett 2003; 197: 137–143.
24 Miller MA, Karacay B, Zhu X, D’Orsio MS, Sandler AD. Caspase 8L, a novel inhibitory isoform of caspase 8 is associated with undifferentiated neuroblastoma. Apoptosis 2006; 11: 15–24.
25 Hopkins-Donaldson S, Bodmer J-L, Balmus Bourlaid K, Brogna CB, Tschopp J, Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000; 60: 4315–4319.
26 Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005; 228: 133–141.
27 Karacay B, Sanilooglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF-κB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004; 11: 681–690.
28 Efron PA, Chen MK, Jyengar M, Dai W, Nagaram A, Beierle EA. Differential response of neuroblastoma cells to TRAIL is independent of PI3K/Akt. J Ped Surg 2006; 41: 1072–1080.
29 Poulati V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor proteins and bcl-2. Cancer Res 2001; 61: 4864–4872.
30 van Noesel MM, Pieters R, Voute PA, Versteege R. The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. Cancer Lett 2003; 197: 165–172.

12 Cell Death Discovery (2016) 16004 © 2016 Cell Death Differentiation Association
Farina AR, Masciulli MP, Tacconelli A, Cappabianca L, De Santis G, Gulino A et al. All-trans-retinoic acid induces nuclear factor kappaB activation and matrix metalloproteinase-9 expression and enhances basal membrane invasivity of differentiation-resistant human SK-N-NE 9N neuroblastoma cells. *Cell Growth Differ* 2002; 13: 343–354.

Scroczek R, Meier B, Mannel DN, Droge W, Baueerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. *J Exp Med* 1992; 175: 1181–1194.

Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. *J Immunol* 2000; 164: 3961–3970.

Moubarak RS, Solé C, Pascual M, Gutierrez H, Llorente M, Perez-Garcia MJ et al. The death receptor antagonist FLIP-L interacts with Trk and is necessary for neurite outgrowth induced by neurotrophins. *J Neurosci* 2010; 30: 6094–6105.

Kantarci C, Walczak H. Caspase-8 and Bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 2011; 1813: 558–563.

Gribnizhler A, Higuchi H, Bronk SF, Gores GJ. cFLIP-L inhibits p38 MAPK activation: an additional anti-apoptotic mechanism in bile acid-mediated apoptosis. *J Biol Chem* 2003; 278: 26831–26837.

Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thomsberry NA. Inhibition of human caspases by peptide based and macromolecular inhibitors. *J Biol Chem* 1998; 273: 32608–32613.

Lawrence CP, Chow SC. Suppression of human T cell proliferation by the caspase inhibitors, z-VAD-FMK and z-IETD-FMK is independent of their caspase inhibition properties. *Toxicol Appl Pharmacol* 2012; 265: 103–112.

Ozören N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry DS. The caspase 9 inhibitor z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. *Cancer Res* 2000; 60: 6259–6265.

Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-activated phosphatase 1 is regulated by Smac/Diablo release from mitochondria. *Cancer Res* 2001; 61: 7339–7348.

van Loo G, van Gurp M, Depuydt B, Srinivasula SM, Rodriguez I, Alnemri ES et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. *Cell Death Differ* 2002; 9: 20–26.

Bul NT, Livolli A, Peyron JF, Prehn JH. Activation of nuclear factor kappaB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IkappaB alpha. *J Cell Biol* 2001; 152: 753–764.

Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. *Oncogene* 2001; 20: 7342–7351.

Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. *Science* 1999; 286: 2358–2361.

Grimes CA, Ijope RS. CREB DNA binding activity is inhibited by glycosen synthase kinase-3 beta and facilitated by lithium. *J Neurochem* 2001; 78: 1219–1232.

Poluha W, Poluha DK, Ross AH. TRK neurogenic receptor regulates differentiation of neuroblastoma cells. *Oncogene* 1995; 10: 185–189.

Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A et al. TRK alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. *Cancer Cell* 2004; 6: 347–360.

Malèfia F, Paolotti E, Bruni Ercol E, Materazzi S, Nassin R, Coppi E et al. Functional characterization of human ProNGF and NGF mutants: identification of NGF P61SR100E as a “painless” lead investigational candidate for therapeutic applications. *PLoS One* 2015; 10: e0136425.

von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. *Cancer Cell* 2015; 27: 1–13.

Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Broedeur GM. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. *Cancer Res* 1991; 51: 1596–1599.

Ballas K, Lyons J, Janssen JWG, Bartram CR. Incidence of ras gene mutation in neuroblastoma. *Eur J Pediatr* 1998; 147: 313–314.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. *Nat Genet* 2015; 47: 864–871.

Zazzeroni F, Papa S, Alarcon-Schimnich A, Alvarez K, Melis T, Bubici C et al. Gadd45beta mediates the protective effects of CD40 co-stimulation against Fas-induced apoptosis. *Blood* 2003; 102: 3270–3279.

Schindelin J, Rueden CT, Hiner MC, Elceci KW. The ImageJ ecosystem: an open platform for biomedical image analysis. *Mol Reprod Dev* 2015; 82: 518–529.

Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. *BMC Biotechnol* 2005; 5: 12–18.

Baskan D, Popovic S, Ristic P, Arsenijevic NN. Analysis of cycloheximide-induced apoptosis in human leukemia: fluorescence microscopy using annexin V/pro-pidium iodide versus acridine orange/ethidium bromide. *Cell Biol Int* 2006; 30: 924–932.

Sprick MR, Weigand MA, Rieser E, Rauch CT, Joo P, Blenis J, Krammer PH et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. *Immunity* 2000; 12: 599–609.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/